Pathogenic role of Epstein-Barr virus latent membrane protein-1 in the development of nasopharyngeal carcinoma

Cancer Letters

Volumn 337, Issue 1, 2013, Pages 1-7

  Yoshizaki, Tomokazu ^a   Kondo, Satoru ^a   Wakisaka, Naohiro ^a   Murono, Shigeyuki ^a   Endo, Kazuhira ^a   Sugimoto, Hisashi ^a   Nakanishi, Sayaka ^a   Tsuji, Akira ^a   Ito, Makoto ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Cancer stem cell; EMT; Epstein Barr virus; LMP1; Nasopharyngeal carcinoma

Indexed keywords

HUMAN HERPESVIRUS 4;

EID: 84880038924     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.018     Document Type: Review

References (107)

1. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D.B. Cancer incidence in five continents. IARC Sci. Publ. 2002, VIII:1-781.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
3. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 2002, 12:431-441.
4. Yoshizaki T. Promotion of metastasis in nasopharyngeal carcinoma by Epstein-Barr virus latent membrane protein-1. Histol. Histopathol. 2002, 17:845-850.
5. Yoshizaki T., Ito M., Murono S., Wakisaka N., Kondo S., Endo K. Current understanding and management of nasopharyngeal carcinoma. Auris Nasus Larynx 2012, 39:137-144.
6. Nielsen N.H., Mikkelsen F., Hansen J.P. Nasopharyngeal cancer in Greenland, The incidence in an Arctic Eskimo population. Acta Pathol. Microbiol. Scand. A 1977, 85:850-858.
7. Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res. 1974, 34:1189-1191.
8. Dickson R.I., Flores A.D. Nasopharyngeal carcinoma: an evaluation of 134 patients treated between 1971-1980. Laryngoscope 1985, 95:276-283.
9. Shanmugaratnam K. Histological typing of nasopharyngeal carcinoma. IARC Sci. Publ. 1978, 3-12.
10. Micheau C., Rilke F., Pilotti S. Proposal for a new histopathological classification of the carcinomas of the nasopharynx. Tumori 1978, 64:513-518.
11. de Schryver A., Friberg S., Klein G., Henle W., Henle G., De-The G., Clifford P., Ho H.C. Epstein-Barr virus-associated antibody patterns in carcinoma of the post-nasal space. Clin. Exp. Immunol. 1969, 5:443-459.
12. Henle W., Henle G., Ho H.C., Burtin P., Cachin Y., Clifford P., de Schryver A., de-The G., Diehl V., Klein G. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J. Natl Cancer Inst. 1970, 44:225-231.
13. Pearson G.R., Weiland L.H., Neel H.B., Taylor W., Earle J., Mulroney S.E., Goepfert H., Lanier A., Talvot M.L., Pilch B., Goodman M., Huang A., Levine P.H., Hyams V., Moran E., Henle G., Henle W. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 1983, 51:260-268.
14. JM N. Nasopharyngeal carcinoma: classification and histological appearances. Adv. Anat. Pathol. 1997, 4:71-84.
15. Reddy S.P., Raslan W.F., Gooneratne S., Kathuria S., Marks J.E. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am. J. Otolaryngol. 1995, 16:103-108.
16. Marks J.E., Phillips J.L., Menck H.R. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer 1998, 83:582-588.
17. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985, 43:831-840.
18. Kieff E., Rickinson A. Epstein-Barr virus and its replication 2007, Lippincott Williams & Wilkins, Philadelphia, PA.
19. Lu J.J., Chen J.Y., Hsu T.Y., Yu W.C., Su I.J., Yang C.S. Induction of apoptosis in epithelial cells by Epstein-Barr virus latent membrane protein 1. J. Gen. Virol. 1996, 77(Pt 8):1883-1892.
20. Liu Y., Wang X., Lo A.K., Wong Y.C., Cheung A.L., Tsao S.W. Latent membrane protein-1 of Epstein-Barr virus inhibits cell growth and induces sensitivity to cisplatin in nasopharyngeal carcinoma cells. J. Med. Virol. 2002, 66:63-69.
21. Zhang X., Hu L., Fadeel B., Ernberg I.T. Apoptosis modulation of Epstein-Barr virus-encoded latent membrane protein 1 in the epithelial cell line HeLa is stimulus-dependent. Virology 2002, 304:330-341.
22. Liu M.T., Chen Y.R., Chen S.C., Hu C.Y., Lin C.S., Chang Y.T., Wang W.B., Chen J.Y. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 2004, 23:2531-2539.
23. Dirmeier U., Hoffmann R., Kilger E., Schultheiss U., Briseno C., Gires O., Kieser A., Eick D., Sugden B., Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus coordinately regulates proliferation with control of apoptosis. Oncogene 2005, 24:1711-1717.
24. Yoshizaki T., Wakisaka N., Pagano J.S. Epstein-Barr virus, Invasion and Metastasis 2005, Caister Academic Press, London, UK, (Chapter 12).
25. Kimura Y., Suzuki D., Tokunaga T., Takabayashi T., Yamada T., Wakisaka N., Yoshizaki T., Murata H., Miwa K., Shoujaku H., Watanabe Y., Yamada N., Ito Y., Yuta A., Takeuchi K., Hosokawa S., Mineta H., Hasegawa Y., Fujimoto Y., Nakashima T., Fujieda S. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005. Auris Nasus Larynx 2011, 38:244-249.
26. Yoshizaki T., Sato H., Furukawa M., Pagano J.S. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA 1998, 95:3621-3626.
27. Horikawa T., Yoshizaki T., Sheen T.S., Lee S.Y., Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000, 89:715-723.
28. Lee D.C., Chua D.T., Wei W.I., Sham J.S., Lau A.S. Induction of matrix metalloproteinases by Epstein-Barr virus latent membrane protein 1 isolated from nasopharyngeal carcinoma. Biomed. Pharmacother. 2007, 61:520-526.
29. Zhao Y., Wang Y., Zeng S., Hu X. LMP1 expression is positively associated with metastasis of nasopharyngeal carcinoma: evidence from a meta-analysis. J. Clin. Pathol. 2012, 65:41-45.
30. Khabir A., Karray H., Rodriguez S., Rose M., Daoud J., Frikha M., Boudawara T., Middeldorp J., Jlidi R., Busson P. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol. J. 2005, 2:39.
31. Kim K.R., Yoshizaki T., Miyamori H., Hasegawa K., Horikawa T., Furukawa M., Harada S., Seiki M., Sato H. Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 2000, 19:1764-1771.
32. Horikawa T., Sheen T.S., Takeshita H., Sato H., Furukawa M., Yoshizaki T. Induction of c-Met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. Am. J. Pathol. 2001, 159:27-33.
33. Endo K., Kondo S., Shackleford J., Horikawa T., Kitagawa N., Yoshizaki T., Furukawa M., Zen Y., Pagano J.S. Phosphorylated ezrin is associated with EBV latent membrane protein 1 in nasopharyngeal carcinoma and induces cell migration. Oncogene 2009, 28:1725-1735.
34. Shair K.H., Schnegg C.I., Raab-Traub N. Epstein-Barr virus latent membrane protein-1 effects on junctional plakoglobin and induction of a cadherin switch. Cancer Res. 2009, 69:5734-5742.
35. Kondo S., Yoshizaki T., Wakisaka N., Horikawa T., Murono S., Jang K.L., Joab I., Furukawa M., Pagano J.S. MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling. J. Virol. 2007, 81:1554-1562.
36. Murono S., Yoshizaki T., Sato H., Takeshita H., Furukawa M., Pagano J.S. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res. 2000, 60:2555-2561.
37. Liu L.T., Peng J.P., Chang H.C., Hung W.C. RECK is a target of Epstein-Barr virus latent membrane protein 1. Oncogene 2003, 22:8263-8270.
38. Kondo S., Wakisaka N., Schell M.J., Horikawa T., Sheen T.S., Sato H., Furukawa M., Pagano J.S., Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int. J. Cancer 2005, 115:368-376.
39. Chew M.M., Gan S.Y., Khoo A.S., Tan E.L. Interleukins, laminin and Epstein - Barr virus latent membrane protein 1 (EBV LMP1) promote metastatic phenotype in nasopharyngeal carcinoma. BMC Cancer 2010, 10:574.
40. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
41. Hui E.P., Chan A.T., Pezzella F., Turley H., To K.F., Poon T.C., Zee B., Mo F., Teo P.M., Huang D.P., Gatter K.C., Johnson P.J., Harris A.L. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin. Cancer Res. 2002, 8:2595-2604.
42. Kondo S., Seo S.Y., Yoshizaki T., Wakisaka N., Furukawa M., Joab I., Jang K.L., Pagano J.S. EBV latent membrane protein 1 up-regulates hypoxia-inducible factor 1alpha through Siah1-mediated down-regulation of prolyl hydroxylases 1 and 3 in nasopharyngeal epithelial cells. Cancer Res. 2006, 66:9870-9877.
43. Nakayama K., Frew I.J., Hagensen M., Skals M., Habelhah H., Bhoumik A., Kadoya T., Erdjument-Bromage H., Tempst P., Frappell P.B., Bowtell D.D., Ronai Z. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological responses to hypoxia. Cell 2004, 117:941-952.
44. Kitagawa N., Kondo S., Wakisaka N., Zen Y., Nakanishi Y., Tsuji A., Endo K., Murono S., Yoshizaki T. Expression of seven-in-absentia homologue 1 and hypoxia-inducible factor 1 alpha: novel prognostic factors of nasopharyngeal carcinoma. Cancer Lett. 2013, 331:52-57.
45. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., Tanzawa K., Thorpe P., Itohara S., Werb Z., Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
46. Murono S., Inoue H., Tanabe T., Joab I., Yoshizaki T., Furukawa M., Pagano J.S. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. USA 2001, 98:6905-6910.
47. Wakisaka N., Murono S., Yoshizaki T., Furukawa M., Pagano J.S. Epstein-barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res. 2002, 62:6337-6344.
48. Wakisaka N., Kondo S., Yoshizaki T., Murono S., Furukawa M., Pagano J.S. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol. Cell. Biol. 2004, 24:5223-5234.
49. Yoshizaki T., Horikawa T., Qing-Chun R., Wakisaka N., Takeshita H., Sheen T.S., Lee S.Y., Sato H., Furukawa M. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin. Cancer Res. 2001, 7:1946-1951.
50. Ren Q., Sato H., Murono S., Furukawa M., Yoshizaki T. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line. Laryngoscope 2004, 114:855-859.
51. Eliopoulos A.G., Gallagher N.J., Blake S.M., Dawson C.W., Young L.S. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 1999, 274:16085-16096.
52. Horikawa T., Kaizaki Y., Kato H., Furukawa M., Yoshizaki T. Expression of interleukin-8 receptor A predicts poor outcome in patients with nasopharyngeal carcinoma. Laryngoscope 2005, 115:62-67.
53. Tsuji A., Wakisaka N., Kondo S., Murono S., Furukawa M., Yoshizaki T. Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma. Clin. Cancer Res. 2008, 14:5368-5375.
54. Wakisaka N., Hirota K., Kondo S., Sawada-Kitamura S., Endo K., Murono S., Yoshizaki T. Induction of lymphangiogenesis through vascular endothelial growth factor-C/vascular endothelial growth factor receptor 3 axis and its correlation with lymph node metastasis in nasopharyngeal carcinoma. Oral Oncol. 2012, 48:703-708.
55. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
56. Martin T.A., Goyal A., Watkins G., Jiang W.G. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann. Surg. Oncol. 2005, 12:488-496.
57. Zheng Z., Pan J., Chu B., Wong Y.C., Cheung A.L., Tsao S.W. Downregulation and abnormal expression of E-cadherin and beta-catenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum. Pathol. 1999, 30:458-466.
58. Tsai C.N., Tsai C.L., Tse K.P., Chang H.Y., Chang Y.S. The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc. Natl. Acad. Sci. USA 2002, 99:10084-10089.
59. Horikawa T., Yang J., Kondo S., Yoshizaki T., Joab I., Furukawa M., Pagano J.S. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res. 2007, 67:1970-1978.
60. Horikawa T., Yoshizaki T., Kondo S., Furukawa M., Kaizaki Y., Pagano J.S. Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma. Br. J. Cancer 2011, 104:1160-1167.
61. Kondo S., Wakisaka N., Muramatsu M., Zen Y., Endo K., Murono S., Sugimoto H., Yamaoka S., Pagano J.S., Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J. Virol. 2011, 85:11255-11264.
62. Han H.J., Russo J., Kohwi Y., Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452:187-193.
63. Endo K., Shackelford J., Aga M., Yoshizaki T., Pagano J.S. Up-regulation of SATB1 by EBV LMP1 in human nasopharyngeal cells and nasopharyngeal cancer. J Gen Virol. 2013, 94:507-513.
64. Kong Q.L., Hu L.J., Cao J.Y., Huang Y.J., Xu L.H., Liang Y., Xiong D., Guan S., Guo B.H., Mai H.Q., Chen Q.Y., Zhang X., Li M.Z., Shao J.Y., Qian C.N., Xia Y.F., Song L.B., Zeng Y.X., Zeng M.S. Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog. 2010, 6:e1000940.
65. Lun S.W., Cheung S.T., Cheung P.F., To K.F., Woo J.K., Choy K.W., Chow C., Cheung C.C., Chung G.T., Cheng A.S., Ko C.W., Tsao S.W., Busson P., Ng M.H., Lo K.W. CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma. PLoS ONE 2012, 7:e52426.
66. Schorey J.S., Bhatnagar S. Exosome function: from tumor immunology to pathogen biology. Traffic 2008, 9:871-881.
67. Simons M., Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 2009, 21:575-581.
68. Houali K., Wang X., Shimizu Y., Djennaoui D., Nicholls J., Fiorini S., Bouguermouh A., Ooka T. A new diagnostic marker for secreted Epstein-Barr virus encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clin. Cancer Res. 2007, 13:4993-5000.
69. Dukers D.F., Meij P., Vervoort M.B., Vos W., Scheper R.J., Meijer C.J., Bloemena E., Middeldorp J.M. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J. Immunol. 2000, 165:663-670.
70. Flanagan J., Middeldorp J., Sculley T. Localization of the Epstein-Barr virus protein LMP 1 to exosomes. J. Gen. Virol. 2003, 84:1871-1879.
71. Muntasell A., Berger A.C., Roche P.A. T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. EMBO J. 2007, 26:4263-4272.
72. Middeldorp J.M., Pegtel D.M. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. Semin. Cancer Biol. 2008, 18:388-396.
73. Buschow S.I., Nolte-'t Hoen E.N., van Niel G., Pols M.S., Ten Broeke T., Lauwen M., Ossendorp F., Melief C.J., Raposo G., Wubbolts R., Wauben M.H., Stoorvogel W. MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic 2009, 10:1528-1542.
74. Hiscott J., Kwon H., Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J. Clin. Invest. 2001, 107:143-151.
75. Meckes D.G., Shair K.H., Marquitz A.R., Kung C.P., Edwards R.H., Raab-Traub N. Human tumor virus utilizes exosomes for intercellular communication. Proc. Natl. Acad. Sci. USA 2010, 107:20370-20375.
76. Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein-Barr virus strains. Virology 1999, 261:79-95.
77. Hu L.F., Zabarovsky E.R., Chen F., Cao S.L., Ernberg I., Klein G., Winberg G. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J. Gen. Virol. 1991, 72(Pt 10):2399-2409.
78. Chen M.L., Tsai C.N., Liang C.L., Shu C.H., Huang C.R., Sulitzeanu D., Liu S.T., Chang Y.S. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992, 7:2131-2140.
79. Hu L.F., Chen F., Zheng X., Ernberg I., Cao S.L., Christensson B., Klein G., Winberg G. Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 1993, 8:1575-1583.
80. Miller W.E., Cheshire J.L., Baldwin A.S., Raab-Traub N. The NPC derived C15 LMP1 protein confers enhanced activation of NF-kappa B and induction of the EGFR in epithelial cells. Oncogene 1998, 16:1869-1877.
81. Dawson C.W., Eliopoulos A.G., Blake S.M., Barker R., Young L.S. Identification of functional differences between prototype Epstein-Barr virus-encoded LMP1 and a nasopharyngeal carcinoma-derived LMP1 in human epithelial cells. Virology 2000, 272:204-217.
82. Blake S.M., Eliopoulos A.G., Dawson C.W., Young L.S. The transmembrane domains of the EBV-encoded latent membrane protein 1 (LMP1) variant CAO regulate enhanced signalling activity. Virology 2001, 282:278-287.
83. Fielding C.A., Sandvej K., Mehl A., Brennan P., Jones M., Rowe M. Epstein-Barr virus LMP-1 natural sequence variants differ in their potential to activate cellular signaling pathways. J. Virol. 2001, 75:9129-9141.
84. Burrows J.M., Bromham L., Woolfit M., Piganeau G., Tellam J., Connolly G., Webb N., Poulsen L., Cooper L., Burrows S.R., Moss D.J., Haryana S.M., Ng M., Nicholls J.M., Khanna R. Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia. J. Virol. 2004, 78:7131-7137.
85. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330.
86. Gulley M.L., Nicholls J.M., Schneider B.G., Amin M.B., Ro J.Y., Geradts J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am. J. Pathol. 1998, 152:865-869.
87. Kwong J., Lo K.W., To K.F., Teo P.M., Johnson P.J., Huang D.P. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 2002, 8:131-137.
88. Song X., Tao Y.G., Deng X.Y., Jin X., Tan Y.N., Tang M., Wu Q., Lee L.M., Cao Y. Heterodimer formation between c-Jun and Jun B proteins mediated by Epstein-Barr virus encoded latent membrane protein 1. Cell. Signal. 2004, 16:1153-1162.
89. Ohtani N., Brennan P., Gaubatz S., Sanij E., Hertzog P., Wolvetang E., Ghysdael J., Rowe M., Hara E. Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5. J. Cell Biol. 2003, 162:173-183.
90. Reed A.L., Califano J., Cairns P., Westra W.H., Jones R.M., Koch W., Ahrendt S., Eby Y., Sewell D., Nawroz H., Bartek J., Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 1996, 56:3630-3633.
91. Hui A.B., Lo K.W., Leung S.F., Teo P., Fung M.K., To K.F., Wong N., Choi P.H., Lee J.C., Huang D.P. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation. Int. J. Cancer 1999, 82:498-503.
92. Lo K.W., Teo P.M., Hui A.B., To K.F., Tsang Y.S., Chan S.Y., Mak K.F., Lee J.C., Huang D.P. High resolution allelotype of microdissected primary nasopharyngeal carcinoma. Cancer Res. 2000, 60:3348-3353.
93. Lo K.W., Cheung S.T., Leung S.F., van Hasselt A., Tsang Y.S., Mak K.F., Chung Y.F., Woo J.K., Lee J.C., Huang D.P. Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res. 1996, 56:2721-2725.
94. Wang G.L., Lo K.W., Tsang K.S., Chung N.Y., Tsang Y.S., Cheung S.T., Lee J.C., Huang D.P. Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br. J. Cancer 1999, 81:1122-1126.
95. Chow L.S., Lo K.W., Kwong J., To K.F., Tsang K.S., Lam C.W., Dammann R., Huang D.P. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int. J. Cancer 2004, 109:839-847.
96. Lo K.W., Huang D.P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol. 2002, 12:451-462.
97. Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., John B., Enright A.J., Marks D., Sander C., Tuschl T. Identification of virus-encoded microRNAs. Science 2004, 304:734-736.
98. Grundhoff A., Sullivan C.S., Ganem D. A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 2006, 12:733-750.
99. Kim do N., Chae H.S., Oh S.T., Kang J.H., Park C.H., Park W.S., Takada K., Lee J.M., Lee W.K., Lee S.K. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J. Virol. 2007, 81:1033-1036.
100. Lo A.K., To K.F., Lo K.W., Lung R.W., Hui J.W., Liao G., Hayward S.D. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc. Natl. Acad. Sci. USA 2007, 104:16164-16169.
101. Imig J., Motsch N., Zhu J.Y., Barth S., Okoniewski M., Reineke T., Tinguely M., Faggioni A., Trivedi P., Meister G., Renner C., Grasser F.A. MicroRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Res. 2011, 39:1880-1893.
102. Sengupta S., den Boon J.A., Chen I.H., Newton M.A., Stanhope S.A., Cheng Y.J., Chen C.J., Hildesheim A., Sugden B., Ahlquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc. Natl. Acad. Sci. USA 2008, 105:5874-5878.
103. Chen H.C., Chen G.H., Chen Y.H., Liao W.L., Liu C.Y., Chang K.P., Chang Y.S., Chen S.J. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br. J. Cancer 2009, 100:1002-1011.
104. Li G., Wu Z., Peng Y., Liu X., Lu J., Wang L., Pan Q., He M.L., Li X.P. MicroRNA-10b induced by Epstein-Barr virus-encoded latent membrane protein-1 promotes the metastasis of human nasopharyngeal carcinoma cells. Cancer Lett. 2010, 299:29-36.
105. Du Z.M., Hu L.F., Wang H.Y., Yan L.X., Zeng Y.X., Shao J.Y., Ernberg I. Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS ONE 2011, 6:e19137.
106. Xia H., Ng S.S., Jiang S., Cheung W.K., Sze J., Bian X.W., Kung H.F., Lin M.C. MiR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem. Biophys. Res. Commun. 2010, 391:535-541.
107. Pathmanathan R., Prasad U., Sadler R., Flynn K., Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 1995, 333:693-698.